📰 Weight Management Program News
Page 4 - Weight Management Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Weight Management Program. Real-time updates on events, politics, business and more.
October 10, 2023
Arkansas saw its obesity rate dip and its national ranking among the fattest states drop -- but those perceived improvements are being met by muted applause among health professionals across the state.
September 8, 2023
Intermittent fasting has undoubtedly garnered a lot of popularity over the years, driven largely by the health and fitness industry for its promise of a safe…
August 21, 2023
Happy Black Business Month! Here are 10 Black owned businesses in Grand Rapids that you should be supporting year round!
August 21, 2023
Happy Black Business Month! Here are 10 Black owned businesses in Grand Rapids that you should be supporting year round!
August 21, 2023
Happy Black Business Month! Here are 10 Black owned businesses in Grand Rapids that you should be supporting year round!
August 21, 2023
Happy Black Business Month! Here are 10 Black owned businesses in Grand Rapids that you should be supporting year round!
August 9, 2023
ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript August 7, 2023 ReShape Lifesciences Inc. beats earnings expectations. Reported EPS is $-0.00108, expectations were $-1.79. Operator: Good afternoon, and thank you for joining the ReShape Lifesciences Second Quarter 2023 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications. […]
August 9, 2023
Michael Miller: Good afternoon, and thank you for joining the ReShape Lifesciences second quarter 2023 earnings call.
July 27, 2023
Welcome to the 2023-2024 year!!! As I begin my tenure as the 10th commissioner of the CIF Southern Section, I would like the opportunity to introduce myself to those of you who do not know me.
July 12, 2023
As the EU looks into cases of suicidal thoughts and self-harm associated with the GLP-1 agonists semaglutide, and liraglutide, Novo Nordisk says it is confident of the risk-benefit profile of these agents.